Advertisement

Topics

Three's a crowd: Tecentriq gets lung cancer nod

04:40 EDT 19 Oct 2016 | BioPharmaDive

Roche hopes to catch rivals Merck and Bristol-Myers Squibb in immuno-oncology. Winning approval in second-line NSCLC is a key step toward that goal. 

Original Article: Three's a crowd: Tecentriq gets lung cancer nod

NEXT ARTICLE

More From BioPortfolio on "Three's a crowd: Tecentriq gets lung cancer nod"

Quick Search
Advertisement
 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...